Neurex/Warner-Lambert SNX-111 head injury pivotal trial resumes, with target completion date in two years.
Executive Summary
NEUREX SNX-111 HEAD TRAUMA TRIAL SCHEDULED FOR COMPLETION IN TWO YEARS, the Menlo Park, Calif.- based company said following the Sept. 3 resumption of the 800-patient Phase III trial being conducted by marketing partner Warner-Lambert. The trial was suspended in July with very few patients enrolled after an analysis of Phase I/II studies found a "disparity" between the drug and placebo groups ("The Pink Sheet" Aug. 4, T&G-8).